Inge G P Geelen

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 7

Top Venues

Annals of hematology

European journal of haematology

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Inge G P Geelen, Stein-Erik Gullaksen, Mette M Ilander, Ulla Olssen-Strömberg, Satu Mustjoki, Johan Richter, Nicole M A Blijlevens, Willem M Smit, Bjorn T Gjertsen, Tobias Gedde-Dahl, Berit Markevärn, Malika M A Koppes, Peter E Westerweel, Henrik Hjorth-Hansen, Jeroen J W M Janssen
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Annals of hematology (2023)
Inge G P Geelen, Stein-Erik Gullaksen, Mette M Ilander, Ulla Olssen-Strömberg, Satu Mustjoki, Johan Richter, Nicole M A Blijlevens, Willem M Smit, Bjorn T Gjertsen, Tobias Gedde-Dahl, Berit Markevärn, Malika M A Koppes, Peter E Westerweel, Henrik Hjorth-Hansen, Jeroen J W M Janssen
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Annals of hematology 102 (6) (2023)
Inge G P Geelen, Stein-Erik Gullaksen, Mette M Ilander, Ulla Olssen-Strömberg, Satu Mustjoki, Johan Richter, Nicole M A Blijlevens, Willem M Smit, Bjorn T Gjertsen, Tobias Gedde-Dahl, Berit Markevärn, Malika M A Koppes, Peter E Westerweel, Henrik Hjorth-Hansen, Jeroen J W M Janssen
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Annals of hematology 102 (6) (2023)
Inge G P Geelen, Stein-Erik Gullaksen, Mette M Ilander, Ulla Olssen-Strömberg, Satu Mustjoki, Johan Richter, Nicole M A Blijlevens, Willem M Smit, Bjorn T Gjertsen, Tobias Gedde-Dahl, Berit Markevärn, Malika M A Koppes, Peter E Westerweel, Henrik Hjorth-Hansen, Jeroen J W M Janssen
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Annals of hematology 102 (6) (2023)
Paul J Hengeveld, Aaram O Khader, Linda H A de Bruin, Inge G P Geelen, Eske A van Baalen, Eva Jansen, Nathalie I Bouwer, Ömer Balak, Jurgen A Riedl, Anton W Langerak, Peter E Westerweel, Mark-David Levin
Blood cell counts and lymphocyte subsets of patients admitted during the COVID-19 pandemic: a prospective cohort study. British journal of haematology 190 (4) (2020)
Inge G P Geelen, Noortje Thielen, Jeroen J W M Janssen, Mels Hoogendoorn, Tanja J A Roosma, Peter J M Valk, Otto Visser, Jan J Cornelissen, Peter E Westerweel
Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe. European journal of haematology 100 (4) (2018)
Inge G P Geelen, Noortje Thielen, Jeroen J W M Janssen, Mark-David Levin, Mels Hoogendoorn, Otto Visser, Jan J Cornelissen, Peter E Westerweel
Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival. European journal of haematology 99 (4) (2017)

Inge G P Geelen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Inge G P Geelen